Host RNA quality control as a hepatitis B antiviral target

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• Hepatitis B virus (HBV) infection necessitates novel therapeutic strategies due to limitations of current treatments.
• Host RNA polyadenylating polymerases PAPD5 and PAPD7 (PAPD5/7), also known as TENT4B/A, play roles in cellular RNA quality control and transcript maturation.
• These polymerases are implicated in the degradation of aberrant cellular transcripts and the maturation of specific RNA subsets.

Purpose of the Study:

• To investigate the antiviral potential of dihydroquinolizinone (DHQ), a small molecule inhibitor of PAPD5/7, against hepatitis B virus (HBV).
• To explore the mechanism by which PAPD5/7 inhibition impacts HBV RNA levels and viral gene expression.
• To evaluate the feasibility of targeting host RNA quality control pathways as a novel antiviral strategy for HBV.

Main Methods:

• Treatment of HBV-infected cells and animal models with dihydroquinolizinone (DHQ).
• Assessment of HBV RNA levels, including pre-genomic, pre-core, and HBsAg mRNA, using molecular assays.
• Analysis of viral gene product expression following PAPD5/7 inhibition.

Main Results:

• DHQ treatment resulted in rapid and selective degradation of HBV RNA.
• Inhibition of PAPD5/7 led to a significant, multi-fold reduction in HBV pre-genomic, pre-core, and HBsAg mRNA levels.
• DHQ demonstrated efficacy in both tissue culture and animal models, indicating its potential as an HBV therapeutic.

Conclusions:

• Inhibition of host PAPD5/7 polymerases by DHQ represents a promising and novel antiviral strategy against HBV.
• Targeting cellular RNA quality control pathways offers a new approach for developing next-generation HBV therapeutics.
• DHQ's selective action on HBV RNA maturation in hepatocytes suggests a targeted therapeutic mechanism with potential for high efficacy.